Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation
Konstantinos C. Siontis(Mayo Clinic), Demosthenes G. Katritsis(Hygeia Hospital), Carlo Pappone(San Raffaele University of Rome), Rukshen Weerasooriya(Université de Bordeaux), Peter A. Noseworthy(Mayo Clinic in Arizona), Mark E. Josephson(Beth Israel Deaconess Medical Center), Pierre Jaı̈s(Université de Bordeaux), David J. Wilber(Loyola University Chicago), Rungroj Krittayaphong(Siriraj Hospital), John P. A. Ioannidis(Innovative Research (United States)), Vincenzo Santinelli(University of Messina), Bernard J. Gersh(Clinical Research Institute), John D. Hummel(The Ohio State University Wexner Medical Center), Carlos A. Morillo(Spanish National Centre for Cardiovascular Research), Douglas L. Packer(WinnMed), Jens Cosedis Nielsen(Aarhus University), Hakan Oral(University of Michigan), George Katritsis(Harefield Hospital)
Cited by 54
Related Papers
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
|Nature Reviews Genetics|2008|3k
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
|Heart Rhythm|2017|2.7k
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
|Circulation|2011|2.1k
Subclinical Atrial Fibrillation and the Risk of Stroke
|New England Journal of Medicine|2012|2.1k
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure
|New England Journal of Medicine|2016|1.7k